Pfizer forecasts about $15 billion in 2021 sales from Covid-19 vaccine

Pfizer said it expects about $15 billion in revenue this year from the Covid-19 vaccine it developed with BioNTech SE, a sign of returns to come from the industry’s pandemic response efforts.

The vaccine projection primarily includes doses that are expected to be delivered this year under existing contracts, Pfizer said Tuesday as it reported fourth-quarter earnings, and it may be adjusted as more contracts are reached.

Pfizer is commanding a higher price for its vaccine than some rivals. Under the terms of its supply deal with the US, it is charging $19.50 for each shot of the two-dose regimen. Rival AstraZeneca,